Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study
Pfizer $PFE and its partner Merck KGaA have run into a dead end in their race to expand the market for their PD-L1 checkpoint Bavencio (avelumab). Researchers today conceded that the checkpoint — one of 5 now scrambling to expand their market turf in the mega-blockbuster global oncology business — failed to significantly improve overall survival for advanced gastric cancer patients compared to best standard of care.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters